<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959606</url>
  </required_header>
  <id_info>
    <org_study_id>SAFE</org_study_id>
    <nct_id>NCT02959606</nct_id>
  </id_info>
  <brief_title>SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study</brief_title>
  <official_title>SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      After endovascular treatment (EVT) for peripheral artery disease (PAD), dual antiplatelet
      therapy (DAAT) of aspirin (ASA) and clopidogrel are currently drug of choice to prevent
      occlusion. Anplone SRÂ®, controlled-released Sarpogrelate hydrochloride, has been introduced
      as an anti-platelet agent for the drug of PAD. The aim of this study was to compare the
      efficacy and safety of Anplone + aspirin and clopidogrel + aspirin in patients who underwent
      EVT for femoro-popliteal occlusive disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restenosis rate (50%&gt;) in 6 months by CT angiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion restenosis(TLR) in 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding complication</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral major amputation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Sarpogrelate SR 300mg + ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.
Other Name: Anplone SR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel + ASA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.
Other Name: Plavix</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarpogrelate SR 300mg</intervention_name>
    <arm_group_label>Sarpogrelate SR 300mg + ASA</arm_group_label>
    <other_name>Anplone SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Clopidogrel + ASA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult, &gt;18 years old

          2. Angiographically-confirmed significant femoro-popliteal (FP) stenosis or occlusion by
             atherosclerosis

          3. Successful FP intervention; residual stenosis &lt;30%

          4. Without significant residual inflow disease; Intact iliac artery inflow (with or
             without intervention of iliac or below knee arteries)

          5. patent outflow status; at least 1 arterial runoff in below knee arteries

          6. All kind of fem-pop intervention including POBA, stent, DCB, DES for TASC A~ D

        Exclusion Criteria:

          1. At risk of hemorrhage, bleeding tendency or thrombophilia

          2. Acute limb ischemia / inflammatory arterial disease

          3. Contraindication or allergic to ASA, clopidogrel, Anplone

          4. Medication of warfarin

          5. Pregnancy, hepatic dysfunction, thrombocytopenia

          6. Previous FP bypass or intervention

          7. Impossible to stop clopidogrel before EVT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seung-Kee Min, MD.PhD.</last_name>
    <phone>+82.2-2072-0297</phone>
    <email>skminmd@snuh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seung-Kee Min,</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Kee Min, MD.</last_name>
      <phone>+82.2-2072-0297</phone>
      <email>skminmd@snuh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Seung-Kee Min</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

